<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/7SF3-7A88" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-12: In Vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time</p><p><b>Protocol Abbreviation:</b> ITA-12</p><p><b>Protocol Version:</b> 3<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/7SF3-7A88>http://dx.doi.org/10.17917/7SF3-7A88</a></p><p><b>Protocol File:</b> protocols/20240411_12-32-23-554_NCL_Method_ITA-12.pdf<p><b>File Title:</b> ITA-12</p><p><b>Description:</b></b> This assay describes the analysis of plasma coagulation via three separate tests: prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). Nanoparticles are incubated with fresh human plasma and assayed for coagulation time, compared to standard controls for each assay, using a coagulometer. When normal plasma is exposed to nanomaterials in vitro, and it results in depletion or inhibition of a certain coagulation factor, a delay in plasma coagulation is expected.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>